Investigación
Grapp-CAIB genera conocimientos válidos de la eficacia y eficiencia de intervenciones innovadoras en prevención y promoción de la salud.
Misión
La misión del Grapp-CAIB es generar conocimientos válidos de la eficacia, efectividad y eficiencia de intervenciones innovadoras en prevención y promoción de la salud y transferirlas a los ciudadanos y a los profesionales, especialmente los de atención primaria, salud pública y los gestores de servicios sanitarios.
La investigación que lleva a cabo en cáncer, factores de riesgo cardiovasculares y otros aspectos de prevención-promoción, es muy aplicada: los conocimientos generados se transfieren a la salud pública o a la clínica de atención primaria.
Principales líneas de investigación
1. Determinantes de la salud, estilos de vida saludables y promoción de hábitos saludables.
A través de esta línea de investigación se pretende estudiar de qué forma las intervenciones basadas en la promoción de estilos de vida saludables pueden contribuir a revertir, tratar y prevenir enfermedades crónicas. Se trata de una línea en la que trabaja un grupo multidisciplinar que incluye a diferentes profesionales de la salud y expertos en áreas como la nutrición, la psicología y la actividad física.
2. Servicios de salud y seguridad del paciente.
La investigación en servicios de salud es un campo científico multidisciplinario que examina cómo la población obtiene acceso a los profesionales de la salud y servicios de atención médica, cuánto cuestan los servicios de salud y qué sucede con los pacientes como resultado de la prestación de estos servicios. Nuestro grupo se enfoca específicamente en las áreas de calidad de la atención médica, seguridad del paciente, atención centrada en el paciente y en el desarrollo y evaluación de intervenciones basadas en salud digital para la prevención y manejo de enfermedades crónicas.
3. Epidemiología para la reducción del riesgo cardiovascular.
Las enfermedades cardiovasculares siguen siendo la principal causa de muerte a nivel mundial. Nuestro grupo de investigación lleva a cabo proyectos dirigidos a obtener un mayor conocimiento sobre la incidencia y la prevalencia de los factores de riesgo cardiovascular, así como de las diversas formas de enfermedad cardiovascular en diferentes países y regiones.
4. Cáncer: epidemiología, prevención y tratamiento.
A través de esta línea de investigación estudiamos de qué forma se pueden mejorar los servicios de atención primaria dirigidos a la prevención del cáncer, así como a su tratamiento, vigilancia y cuidados paliativos.
5. Investigación clínica en atención primaria.
La investigación clínica que lleva nuestro grupo en el ámbito de la atención primaria tiene por objetivo generar nuevos conocimientos que ayuden al diagnóstico, tratamiento y prevención de enfermedades en humanos.
6. Atención de enfermería.
El objetivo de esta línea es desarrollar y promover acciones de enfermería para la promoción y coordinación de la investigación multidisciplinar y traslacional en el cuidado, favoreciendo el vínculo entre la práctica y la investigación, y posibilitando la implementación de una atención segura y de calidad que mejore la salud del paciente. Esta línea forma parte del Centro Español para los Cuidados de Salud Basada en la Evidencia (CECBE), que forma parte de la Colaboración Internacional Joanna Briggs de la unidad de investigación Investén-isciii del Instituto de Investigaciones Sanitarias Carlos III.
7. Infancia y medio ambiente.
El objetivo de esta línea es estudiar el papel de los contaminantes ambientales más importantes en el aire, el agua y la dieta durante el embarazo y el inicio de la vida, y sus efectos en el crecimiento y desarrollo infantil.


Proyectos
Proyectos liderados por GRAPP-caIB en los últimos 3 años
Impulsando la transferencia de DiabeText, una herramienta digital integrada con la historia clínica para mejorar la salud y calidad de vida de personas con diabetes
IP: Ignacio Ricci Cabello
Financiación: 149.500
Duración: 2023-2024
Expediente contrato/proyecto: PDC2022-133257-I00
Investigadores colaboradores: Claudio Mirasso Santos, Aina Yáñez Juan, Miquel Bennasar Veny, Esperança Amengual Alcover, Jordi Llabrés Bordoy, Elena Gervilla García, Silvia Ortín González, Escarlata Angullo Martínez, Carlos Enrique Herrero, María Asunción Boronat Moreiro, Sofía Mira Martínez, María Zaforteza Dezcallar, María Jesús Serrano Ripoll, María Antònia Fiol de Roque, Rocío Zamanillo Campos.
Methodological Support for the Performance of Literature Reviews within Evidence-based Scientific Assessments.
IP Baleares: Ignacio Ricci Cabello
Financiación: 4.000.000€
Duración: 2022-2026
Expediente contrato/proyecto: OC/EFSA/MESE/2022/03
Investigadores colaboradores: María Adoración Romaguera, Miquel BennAsar Veny
Multimorbilidad en el Sistema Nacional de Salud: Caracterización poblacional e impacto de sus patrones y trayectorias en personas mayores (Proyecto MM-SNS)
IP: Angélica Miguélez Chamorro
Financiación: 33.880,00 €
Duración: 2023-2025
Expediente contrato/proyecto: PI22/01684
Investigadores colaboradores: Bernardino Oliva Fanlo, Patricia Lorente Montalvo, Miguel Bennasar Veny, Joan Llobera Cànaves, Aina Maria Yañez Juan, Maria Antònia Fiol de Roque, Estefania Serratusell Sabater
Intervención de Audit &Feedback para reducir la prescripción Inadecuada de Medicación en pacientes mayores de 65 años en atención primaria. Estudio AIM : Ensayo clínico multicéntrico.
IP: Alfonso Leiva Rus
Financiación: 75.020,00 €
Duración: 2023-2025
Expediente contrato/proyecto: PI22/01669
Investigadores colaboradores: Catalina Vicens Caldentey, Aina Maria Yañez Juan, Mónica Martínez Cengotitabengoa, Ermengol Sempere Verdú, Marta Llarena Fernández, Rita Sainz de Rozas Aparicio, Itxasne Lekue Alkorta, Alba Gallego Royo, Isabel Maria Socias Buades, Agustín González Vicens, Francesc Company Bezares, Maria Lluisa Sastre Martorell, Sebastián Jaume Gayà, Cruz Belén Bartolomé Moreno, Ferrán Bejarano Romero
Intervención de Audit & Feedback para reducir la prescripción de antibióticos en Atención Primaria (Estudio AFA).
IP: Laura Gallardo Alfaro (IP), Aina Soler Mieras (Co-IP)
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 38.720,00 €
Duración: 2023-2025
Expediente contrato/proyecto: PI22/01742
Investigadores colaboradores: Rafael Torres García, Antònia Roca Casas, Isabel Maria Socias Buades, Kaoutar Ziani Akrirout, Sofía Mira Martínez, Francesc Company Bezares.
Evaluación de SINERGIAPS, una intervención dirigida a mejorar la seguridad del paciente en centros de salud en España en base a las percepciones y experiencias de los propios pacientes.
IP: Ignacio Ricci Cabello
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 119.790,00 €
Duración: 2023-2025
Expediente contrato/proyecto: PI22/01521
Investigadores colaboradores: José María Valderas, Antonio Olry de Labry Lima, Maria Antonia Fiol de Roque, Sara Guerrero, María Costa Marín, Clara González Formoso, Fernando Isidro Lago, Sofía Mira Martínez
Cohorte IMPaCT. Programa de Medicina Predictiva. Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología (IMPaCT).
IP Baleares: Joan Llobera Cànaves (IP), Xènia Chela Álvarez (coordinadora técnica)
Agencia financiadora: Instituto de Salud Carlos III
Financiación: 233.909,94 €
Duración: 2021-2024
Expediente contrato/proyecto: IMP/00021
Investigadores colaboradores Baleares: Antònia Salvà Fiol, Noemí Pérez García, Eugenia Carandell Jäger, Antònia Roca Casas, Joana Maria Taltavull Aparicio, Oana Bulilete, Joana Ripoll Amengual, Jerònia Miralles Xamena, Caterina Vicens Caldentey
Salud pública y Medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la CohorteIMPaCT (Obes-IMPaCT)
Agencia financiadora: Instituto de Salud Carlos III
Duración: 2024-2026
Expediente contrato/proyecto: PMP22/00003
Investigadores colaboradores Baleares: Joan Llobera Cànaves, José Ignacio Ramírez Manent, Catalina Villalonga Munar
Validación de la ecografía pulmonar, realizada por médicos de familia, como prueba de imagen inicial para diagnosticar neumonía en pacientes COVID-19
IP: José Ignacio Ramírez Manent
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 37,510€
Duración: 2022-2024
Expediente contrato/proyecto: PI21/01521
Investigadores colaboradores: Antonia Roca Casas, Ignacio Ramírez Manent, Magdalena Esteva Cantó, Miguel Román Rodríguez, José Corcoll Reixach, Antonio Albaladejo Dávalos, Cristina Gadea Ruíz, Álvaro Moran Bayón.
¿Cómo se pueden reducir de forma efectiva las prescripciones potencialmente inapropiadas en Atención Primaria? Estudio exploratorio para el diseño de una intervención basada en la evidencia.
IP: María Antònia Fiol de Roque
Agencia financiadora: Instituto de Investigacion Sanitaria Illes Balears (IdISBa). Convocatoria intramural IMPETUS 2021
Financiación: 10,000€
Duración: 2022-2023
Expediente contrato/proyecto: IMP21/02
Investigadores colaboradores: Ignacio Ricci Cabello, Aina Soler Mieras, Maria Jesús Serrano-Ripoll, David Medina Bombardó, Elena Gervilla.
Efectividad clínica y erradicación bacteriológica de 4 pautas antibióticas cortas en infecciones urinarias bajas en mujeres adultas (Estudio SCOUT).
IP: Alfonso Leiva Rus
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 82,500€
Duración: dos años (enero 2021- diciembre 2022)
Expediente contrato/proyecto: ICI20/00128
Investigadores colaboradores: Antonia Roca Casas, José Ignacio Ramírez Manent, Joan Llobera Canaves, Antonio Ballester Camps, Catalina Vicens Caldentey, Aina MariaYañez Juan, Ignacio Ricci Cabello, Aina Soler Mieras, Eva Alcoceba Cruixent, Maria Consuelo Corrionero Soto, Joana Ripoll Amengual
Desarrollo y evaluación de la efectividad, coste-efectividad e implementación de una intervención digital multicomponente de baja intensidad para prevenir diabetes mellitus tipo 2 desde el ámbito de la atención primaria: estudio PREDIABETEXT
IP:Ignacio Ricci Cabello (IP), Escarlata Angullo Martínez (Co-IP)
Agencia financiadora: Instituto de Investigación Sanitaria Illes Balears (IdISBa) – convocatoria intramural Sinergias 2020
Financiación: 20,000€
Duración:2 años (enero 2021- diciembre 2022)
Expediente contrato/proyecto: SYN20/04
Investigadores colaboradores: Maria Jesús Serrano Ripoll, Maria Antonia Fiol de Roque, Joan Llobera Canaves, Alfonso Leiva Rus, Oana, BulileteBulilete, JadwigaKonieczna, Elena Gervilla, Miquel Roca Bennasar, Margalida Gili Planas, Mauro García-Toro, Miquel Bennasar Veny, Aina MariaYañez Juan, Aina Galmés Panadés, Maria Adoración Romaguera Bosch, Rafa Jiménez López, Catalina Vicens Caldentey, Rocío Gómez Juanes, Clara Vidal Thomás, Juan José Montaño Moreno
Proyecto de evaluación y actualización de los indicadores de las principales comorbilidades y complicaciones de la diabetes mellitus tipo 2: el caso de la insuficiencia cardiaca.
IP: Ignacio Ricci Cabello (IP), Rocío Zamanillo Campos (Co-IP)
Agencia financiadora: Astrazeneca
Financiación: 20,000€
Duración: 1 año (enero 2021 – diciembre 2021)
Expediente contrato/proyecto: PSID/INDICA
Efectividad y coste-utilidad de la intervención cognitivo-conductual en la consulta de enfermeras y médicos de atención primaria para el tratamiento del insomnio persistente.
IP: Susana González, Isabel Torrens (coIPs)
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 26,620€
Duración: 2019 – 2021
Expediente contrato/proyecto: PI19/00029
Investigadores colaboradores: Jerónima Miralles, Clara Vidal, Rosa Pizá, Apol•lonia Esteva, Marta Pisà, Patricia Lorente, Catalina Vicens
Cohorte DESVELA. Análisis del papel de las aptitudes personales como determinantes de la incidencia de morbilidad, estilos de vida, calidad de vida, uso de servicios y mortalidad.
IP: Joan Llobera
Agencia financiadora: Proyectos de investigación en salud. Instituto de Salud Carlos III.
Financiación: 27,890.50€
Duración: 2019-2022
Expediente contrato/proyecto: PI19/01868
Investigadores colaboradores: David Medina, Jose María Coll, Matías Torrent, Catalina Vicens, Joana Ripoll, Clara Vidal, Oana Bulilete.
Desarrollo, evaluación e implementación a gran escala de PSICOVIDAPP, una intervención psicoeducativa a través de una aplicación móvil para mitigar problemas de salud mental en profesionales sanitarios actuando frente a la pandemia por COVID-19.
IP: Mauro García Toro (IP), Ignacio Ricci Cabello (Co-IP)
Agencia financiadora: Becas Fundación Española de Psiquiatría y Salud Mental 2020.
Financiación: 41,000€
Duración:14 meses (octubre 2020 – diciembre 2021)
Expediente contrato/proyecto: SEP20/01
Investigadores colaboradores: Miquel Bennasar Veny, Maria Antonia Fiol de Roque, Elena Gervilla García, Rafael Jiménez López, Alfonso Leiva Rus, Joan Llobera Canaves, Joan Salvà Coll, Maria Jesús Serrano Ripoll, Rocío Zamanillo Campos, Aina Maria Yáñez Juan, Carolina Sitges, Javier García Campayo, Maria Esther García Buades, Guadalupe Pastor Moreno, Isabel Ruíz Pérez, Pablo Alonso Coello
Estudio de cohortes retrospectivo para valorar el impacto pronóstico de la exposición a fármacos de riesgo COVID-19
IP:Aina Soler Mieras
Agencia financiadora: Instituto de Investigación Sanitaria Illes Balears (IdISBa) – convocatoria extraordinaria de expresiones de interés para proyectos de investigación en respuesta a la pandemia por COVID-19 .
Financiación: 9,600€
Duración: 2020 – 2021
Expediente contrato/proyecto: COVID-19/26
Investigadores colaboradores: Amaia Alcorta Lorenzo, Ana Aretio, Gemma Arrufat, Guillem Marc Campins Adrover, Francesc Company Bezares, Barbara Ferrer Jaillard, Angel García Álvarez, Aurelia Iglesias Iglesias, Olatz Pérez Rodríguez, Francisca Ramis Riera, Marta Rovira Vila, Mª Luisa Sastre Martorell, Raquel Seco Melantuche, Ana Vanrell Ballestero, Magdalena Esteva Cantó.
Evolución de la seroprevalencia frente al SARS-CoV-2 en población adulta sana de las Islas Baleares.
IP: Joan Llobera Canaves y Antonio Gayà Oliver.
Agencia financiadora: Instituto de Investigación Sanitaria Illes Balears (IdISBa) – convocatoria extraordinaria de expresiones de interés para proyectos de investigación en respuesta a la pandemia por COVID-19
Financiación: 42,680€
Duración: 2020 – 2021
Expediente contrato/proyecto: COVID-19/10
Investigadores colaboradores: OanaBulilete, Javier Calvo Benito, Enrique Girona Llobera, Alfonso Leiva Rus, Antonio Oliver Palomo, Maties Torrent Quetglas.
Efectividad de una intervención basada en el uso de tecnología móvil para la prevención de problemas de salud mental en profesionales sanitarios en primera línea de atención de pacientes con COVID-19.
IP: Ignacio Ricci Cabello y Maria Jesús Serrano Ripoll
Agencia financiadora: Instituto de Investigación Sanitaria Illes Balears (IdISBa) – convocatoria extraordinaria de expresiones de interés para proyectos de investigación en respuesta a la pandemia por COVID-19
Financiación: 48,500€
Duración:18 meses (mayo 2020- noviembre 2021)
Expediente contrato/proyecto: COVID-19/06
Investigadores colaboradores: Miquel Bennasar Veny, Maria Antonia Fiol de Roque, Mauro García Toro, Elena Gervilla García, Rafael Jiménez López, Alfonso Leiva Rus, Joan Llobera Canaves, Joan Salvà Coll, Maria Jesús Serrano Ripoll, Rocío Zamanillo Campos, Aina Maria Yáñez Juan, Carolina Sitges, Javier García Campayo, Maria Esther García Buades, Guadalupe Pastor Moreno, Isabel Ruíz Pérez, Pablo Alonso Coello
Impacto del confinamiento por COVID-19 en los estilos de vida y el bienestar emocional de la población adulta de las Illes Balears (COVID-19/23)
Proyectos de investigación sobre el SARSCoV-2 y la COVID-19. GOIB-IdISBa.
Investigadora principal: Joana Ripoll Amengual.
Duración: 2020 – 2021.
Promoviendo la adherencia a medicación antidiabética en pacientes con diabetes tipo 2 mediante un sistema de tecnología móvil integrado con historias clínicas informatizadas (RTI2018-096935-A-I00)
Proyectos I+D+i “Retos investigación”. Ministerio de Ciencia, Innovación y Universidades.
Investigador principal: Ignacio Ricci Cabello.
Duración: 2019 – 2022.
Prevención de la depresión en el medio laboral mediante una intervención personalizada basada en algoritmos de riesgo, TIC y sistemas de ayuda a las decisiones: ensayo controlado aleatorio (PI18/01306)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigador principal: Alfonso Leiva Rus.
Duración: 2019 – 2021.
Diagnóstico de cáncer en atención primaria: el valor de la intuición del médico de familia GUT FEELINGS (PI18/01462)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigadores principales: Magdalena Esteva Cantó y Bernardino Oliva Fanlo.
Duración: 2019 – 2021.
Necesidades de información e investigación en cáncer de mama desde la perspectiva de las pacientes y los profesionales
Beca V Edición de los Premios Fundación DISA
de Investigación Biomédica 2019. Investigadora principal: Beatriz León Salas (FISSC).
Coinvestigadora principal: Magdalena Esteva Cantó.
Duración: 2019 – 2020.
Diseño de una intervención para la prevención de la depresión en pacientes con sintomatología subclínica a través de la promoción de estilos de vida saludable mediante el uso de una aplicación (App) para smartphone: un estudio formativo (PI005_20)
VII Ayudas Proyectos Investigación AP Mallorca 2020. GAP Mallorca.
Investigadora principal: Mª Jesús Serrano Ripoll.
Duración: 2020 – 2021.
Proyecto de evaluación y actualización de los indicadores de las principales comorbilidades y complicaciones de la diabetes mellitus tipo 2: el caso de la insuficiencia cardiaca (PSID/INDICA) AstraZeneca.
Investigador principal: Ignacio Ricci Cabello.
Duración: 2020 – 2021.
Traducción al catalán y validación psicométrica del cuestionario “Patient Reported Experiences and Outcomes of Safety in Primary Care” PREOS-PC (INAP/SERRANO)
VI Ayudas Proyectos Investigación AP Mallorca 2019. GAP Mallorca.
Investigadora principal: Mª Jesús Serrano Ripoll.
Duración: 2019 – 2020.
Evaluación de la implementación de la ecografía clínica en el área de Atención Primaria de Mallorca (INAP/BULILETE)
VI Ayudas Proyectos Investigación AP Mallorca 2019. GAP Mallorca.
Investigadora principal: Oana Bulilete.
Duración: 2019 – 2020.
Efectividad del automanejo de la medicación, la automonitorización de la presión arterial, dieta y ejercicio físico en la reducción de la presión arterial en pacientes de difícil control (AMADEF) (PI17/02108)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigadores principales: Fabián Unda Villafuerte y Fernando Rigo Carratalà.
Duración: 2018 – 2022.
Development and Evaluation of an Intervention based on the Provision of Patient Feedback to Improve Patient Safety in Spanish Primary Care Centres (CP17/00017)
Contrato Miguel Servet Tipo I. Instituto de Salud Carlos III.
Investigador principal: Ignacio Ricci Cabello.
Duración: 2018 – 2021.
Camareras de piso y salud (ITS 17-096)
II Convocatoria de ayudas del impuesto de turismo sostenible. GOIB.
Investigador principal: Joan Llobera Cànaves.
Duración: 2018 – 2021.
Eficacia del programa de ejercicios de otago aplicado de forma grupal versus individual en la probabilidad de caídas de personas entre 65-80 años no institucionalizadas (PI16/01316)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigadora principal: Jerónima Miralles Xamena.
Duración: 2017 – 2021.
Ensayo clínico, pragmático, abierto con evaluador cegado, aleatorizado para evaluar la eficacia de mantener el tratamiento farmacológico en pacientes con demencia avanzada (PI16/00720)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigadora principal: Aina Soler Mieras.
Duración: 2017 – 2021.
Efectividad del uso de tecnologías de la información y comunicación en el incremento de actividad física y pérdida de peso en sujetos obesos y sedentarios. ECA. Estudio EVIDENT III (PI16/00421)
Proyectos de investigación en salud. Instituto de Salud Carlos III.
Investigador principal: José Ignacio Ramírez Manent.
Duración: 2017 – 2021.
Investigación sobre los efectos sociosanitarios de la COVID-19 entre la población migrante: el ejemplo de Son Gotleu (Palma). II Convocatoria de investigación de impacto social aplicada al desarrollo humano sostenible en el contexto de la COVID-19.
Oficina de Cooperación al Desarrollo y Solidaridad, UIB.
Investigadora principal: Mª de Lluc Bauzà Amengual.
Duración: 2021
Publicaciones científicas

2025
AbstractURLBibTeXEndNoteDOIBibSonomy1.Mira-Martínez S, Malih N, Angullo-Martínez E, Zamanillo-Campos R, Yañez AM, Bennasar-Veny M, Gómez-Juanes R, Konieczna J, Jiménez R, Serrano-Ripoll MJ, Fiol deRoque MA, Leiva A, Galmes-Panades AM, Miralles-Xamena J, Vidal-Thomàs MC, Gómez-Cobo C, Gervilla E, Oña-Gil JI, Ricci-Cabello I. A Multifaceted Digital Intervention for the Prevention of Type 2 Diabetes Mellitus in Primary Care (PREDIABETEXT): Cluster Randomized Trial. Journal of medical Internet research [Internet]. Canada; 2025 Oct.;27:e70981-e70981. https://pubmed.ncbi.nlm.nih.gov/41067715BACKGROUND: The diabetes epidemic continues to surge worldwide, demanding urgent and innovative solutions. Digital health interventions, particularly those targeting behavior change, hold promise due to their affordability and scalability. However, research in this field remains in its early stages. OBJECTIVE: This study aimed to evaluate the effectiveness of PREDIABETEXT (Prediabetes Text Message Digital Intervention for the Prevention of Type 2 Diabetes Mellitus), a digital health intervention, in reducing glycated hemoglobin (HbA(1c)) and in improving secondary clinical, physiological, and behavioral outcomes. METHODS: We conducted a 6-month, 3-arm, pragmatic cluster randomized clinical trial. We recruited patients with prediabetes (HbA(1c) levels between 6% and 6.4% in the previous 3 months or 2 consecutive fasting plasma glucose measurements of 110-125 mg/dL) registered at primary care centers in the Balearic Islands, Spain. The PREDIABETEXT intervention consisted of 3 personalized SMS text messages per week aimed at supporting lifestyle behavior changes and online training for their primary health care professionals. A total of 58 professionals (clusters) from 16 centers participated in the study and were randomized (1:1:1) to intervention group A (patient SMS text messaging), intervention group B (patient SMS text messaging+health care professional web-based training), or the control group (usual care). Following the 6-month intervention period, we conducted individual qualitative interviews with 8 patients and 7 health care professionals to evaluate their experiences with the intervention in terms of utility, satisfaction, and implementation barriers. RESULTS: In total, 58 health care professionals (clusters) were included, allocated to the control group (n=20, 34%; 119/365, 32.6% patients), intervention group A (SMS text messaging only; n=18, 31%; 106/365, 29% patients), and intervention group B (SMS text messaging+training; n=20, 34%; 140/365, 38.4% patients). The mean age of the patients was 59.79 (SD 9.75) years, and 54.5% (199/365) were female. The results of the intention-to-treat analysis at the 6-month time point showed that intervention A led to a small, nonsignificant reduction in HbA(1c) levels compared to the control group (β=-0.05, 95% CI -0.21 to 0.10; P=.50), whereas intervention B showed a similar nonsignificant reduction (β=-0.04, 95% CI -0.12 to 0.10; P=.56). No substantial differences were observed in the remaining secondary outcomes. Interviews revealed positive feedback from patients, who appreciated the intervention's dietary messages and their frequency and practicality. Participants suggested enhancements such as increased personalization, links to recipes, and nursing follow-ups. Health care professionals valued the online training but highlighted time constraints, suggesting shorter or blended formats to improve accessibility. CONCLUSIONS: While PREDIABETEXT did not significantly improve HbA(1c) levels, it demonstrated potential benefits for patient engagement. Further studies involving more intensive interventions are warranted to confirm the clinical impact on diabetes prevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05110625; https://www.clinicaltrials.gov/study/NCT05110625. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.3390/ijerph192214706.@article{miramartinez2025multifaceted,
abstract = {BACKGROUND: The diabetes epidemic continues to surge worldwide, demanding urgent and innovative solutions. Digital health interventions, particularly those targeting behavior change, hold promise due to their affordability and scalability. However, research in this field remains in its early stages. OBJECTIVE: This study aimed to evaluate the effectiveness of PREDIABETEXT (Prediabetes Text Message Digital Intervention for the Prevention of Type 2 Diabetes Mellitus), a digital health intervention, in reducing glycated hemoglobin (HbA(1c)) and in improving secondary clinical, physiological, and behavioral outcomes. METHODS: We conducted a 6-month, 3-arm, pragmatic cluster randomized clinical trial. We recruited patients with prediabetes (HbA(1c) levels between 6% and 6.4% in the previous 3 months or 2 consecutive fasting plasma glucose measurements of 110-125 mg/dL) registered at primary care centers in the Balearic Islands, Spain. The PREDIABETEXT intervention consisted of 3 personalized SMS text messages per week aimed at supporting lifestyle behavior changes and online training for their primary health care professionals. A total of 58 professionals (clusters) from 16 centers participated in the study and were randomized (1:1:1) to intervention group A (patient SMS text messaging), intervention group B (patient SMS text messaging+health care professional web-based training), or the control group (usual care). Following the 6-month intervention period, we conducted individual qualitative interviews with 8 patients and 7 health care professionals to evaluate their experiences with the intervention in terms of utility, satisfaction, and implementation barriers. RESULTS: In total, 58 health care professionals (clusters) were included, allocated to the control group (n=20, 34%; 119/365, 32.6% patients), intervention group A (SMS text messaging only; n=18, 31%; 106/365, 29% patients), and intervention group B (SMS text messaging+training; n=20, 34%; 140/365, 38.4% patients). The mean age of the patients was 59.79 (SD 9.75) years, and 54.5% (199/365) were female. The results of the intention-to-treat analysis at the 6-month time point showed that intervention A led to a small, nonsignificant reduction in HbA(1c) levels compared to the control group (β=-0.05, 95% CI -0.21 to 0.10; P=.50), whereas intervention B showed a similar nonsignificant reduction (β=-0.04, 95% CI -0.12 to 0.10; P=.56). No substantial differences were observed in the remaining secondary outcomes. Interviews revealed positive feedback from patients, who appreciated the intervention's dietary messages and their frequency and practicality. Participants suggested enhancements such as increased personalization, links to recipes, and nursing follow-ups. Health care professionals valued the online training but highlighted time constraints, suggesting shorter or blended formats to improve accessibility. CONCLUSIONS: While PREDIABETEXT did not significantly improve HbA(1c) levels, it demonstrated potential benefits for patient engagement. Further studies involving more intensive interventions are warranted to confirm the clinical impact on diabetes prevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05110625; https://www.clinicaltrials.gov/study/NCT05110625. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.3390/ijerph192214706.},
address = {Canada},
author = {Mira-Martínez, Sofía and Malih, Narges and Angullo-Martínez, Escarlata and Zamanillo-Campos, Rocío and Yañez, Aina M and Bennasar-Veny, Miquel and Gómez-Juanes, Rocío and Konieczna, Jadwiga and Jiménez, Rafael and Serrano-Ripoll, Maria J and Fiol deRoque, Maria Antonia and Leiva, Alfonso and Galmes-Panades, Aina M and Miralles-Xamena, Jerónima and Vidal-Thomàs, Maria Clara and Gómez-Cobo, Cristina and Gervilla, Elena and Oña-Gil, José Iván and Ricci-Cabello, Ignacio},
journal = {Journal of medical Internet research},
keywords = {evisap},
month = {oct},
pages = {e70981--e70981},
title = {A Multifaceted Digital Intervention for the Prevention of Type 2 Diabetes Mellitus in Primary Care (PREDIABETEXT): Cluster Randomized Trial},
volume = 27,
year = 2025
}%0 Journal Article
%1 miramartinez2025multifaceted
%A Mira-Martínez, Sofía
%A Malih, Narges
%A Angullo-Martínez, Escarlata
%A Zamanillo-Campos, Rocío
%A Yañez, Aina M
%A Bennasar-Veny, Miquel
%A Gómez-Juanes, Rocío
%A Konieczna, Jadwiga
%A Jiménez, Rafael
%A Serrano-Ripoll, Maria J
%A Fiol deRoque, Maria Antonia
%A Leiva, Alfonso
%A Galmes-Panades, Aina M
%A Miralles-Xamena, Jerónima
%A Vidal-Thomàs, Maria Clara
%A Gómez-Cobo, Cristina
%A Gervilla, Elena
%A Oña-Gil, José Iván
%A Ricci-Cabello, Ignacio
%C Canada
%D 2025
%J Journal of medical Internet research
%P e70981--e70981
%R 10.2196/70981
%T A Multifaceted Digital Intervention for the Prevention of Type 2 Diabetes Mellitus in Primary Care (PREDIABETEXT): Cluster Randomized Trial
%U https://pubmed.ncbi.nlm.nih.gov/41067715
%V 27
%X BACKGROUND: The diabetes epidemic continues to surge worldwide, demanding urgent and innovative solutions. Digital health interventions, particularly those targeting behavior change, hold promise due to their affordability and scalability. However, research in this field remains in its early stages. OBJECTIVE: This study aimed to evaluate the effectiveness of PREDIABETEXT (Prediabetes Text Message Digital Intervention for the Prevention of Type 2 Diabetes Mellitus), a digital health intervention, in reducing glycated hemoglobin (HbA(1c)) and in improving secondary clinical, physiological, and behavioral outcomes. METHODS: We conducted a 6-month, 3-arm, pragmatic cluster randomized clinical trial. We recruited patients with prediabetes (HbA(1c) levels between 6% and 6.4% in the previous 3 months or 2 consecutive fasting plasma glucose measurements of 110-125 mg/dL) registered at primary care centers in the Balearic Islands, Spain. The PREDIABETEXT intervention consisted of 3 personalized SMS text messages per week aimed at supporting lifestyle behavior changes and online training for their primary health care professionals. A total of 58 professionals (clusters) from 16 centers participated in the study and were randomized (1:1:1) to intervention group A (patient SMS text messaging), intervention group B (patient SMS text messaging+health care professional web-based training), or the control group (usual care). Following the 6-month intervention period, we conducted individual qualitative interviews with 8 patients and 7 health care professionals to evaluate their experiences with the intervention in terms of utility, satisfaction, and implementation barriers. RESULTS: In total, 58 health care professionals (clusters) were included, allocated to the control group (n=20, 34%; 119/365, 32.6% patients), intervention group A (SMS text messaging only; n=18, 31%; 106/365, 29% patients), and intervention group B (SMS text messaging+training; n=20, 34%; 140/365, 38.4% patients). The mean age of the patients was 59.79 (SD 9.75) years, and 54.5% (199/365) were female. The results of the intention-to-treat analysis at the 6-month time point showed that intervention A led to a small, nonsignificant reduction in HbA(1c) levels compared to the control group (β=-0.05, 95% CI -0.21 to 0.10; P=.50), whereas intervention B showed a similar nonsignificant reduction (β=-0.04, 95% CI -0.12 to 0.10; P=.56). No substantial differences were observed in the remaining secondary outcomes. Interviews revealed positive feedback from patients, who appreciated the intervention's dietary messages and their frequency and practicality. Participants suggested enhancements such as increased personalization, links to recipes, and nursing follow-ups. Health care professionals valued the online training but highlighted time constraints, suggesting shorter or blended formats to improve accessibility. CONCLUSIONS: While PREDIABETEXT did not significantly improve HbA(1c) levels, it demonstrated potential benefits for patient engagement. Further studies involving more intensive interventions are warranted to confirm the clinical impact on diabetes prevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT05110625; https://www.clinicaltrials.gov/study/NCT05110625. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.3390/ijerph192214706.
AbstractURLBibTeXEndNoteDOIBibSonomy1.Bescos R, Gallardo-Alfaro L, Ashor A, Rizzolo-Brime L, Siervo M, Casas-Agustench P. Nitrate and nitrite bioavailability in plasma and saliva: Their association with blood pressure - A systematic review and meta-analysis. Free radical biology & medicine [Internet]. United States; 2025 Jan.;226:70-83. https://pubmed.ncbi.nlm.nih.gov/39522567In this study, we conducted a systematic review and meta-analysis to determine plasma and salivary nitrate (NO(3)(-)) and nitrite (NO(2)(-)) concentrations under resting and fasting conditions in different type of individuals and their association with blood pressure levels. A total of 77 studies, involving 1918 individuals aged 19-74 years (males = 906; females = 1012), which measured plasma and/or salivary NO(3)(-) and NO(2)(-) using the chemiluminescence technique, were included. Mean plasma NO(3)(-) and NO(2)(-) concentrations were 33.9 μmol/L and 158.3 nmol/L, respectively. Subgroup analyses revealed lower plasma NO(3)(-) and NO(2)(-) concentrations in individuals with cardiometabolic risk (NO(3)(-): 21.2 μmol/L; 95 % CI, 13.4-29.0; NO(2)(-): 122.8 nmol/L; 95 % CI, 75.3-138.9) compared to healthy (NO(3)(-): 33.9 μmol/L; 95 % CI, 29.9-37.9; NO(2)(-): 159.5 nmol/L; 95 % CI, 131.8-187.1; P < 0.01) and trained individuals (NO(3)(-): 43.0 μmol/L; 95 % CI, 13.2-72.9; NO(2)(-): 199.3 nmol/L; 95 % CI, 117.6-281; P < 0.01). Mean salivary NO(3)(-) and NO(2)(-) concentrations were 546.2 μmol/L and 197.8 μmol/L, respectively. Salivary NO(3)(-), but no NO(2)(-), concentrations were higher in individuals with cardiometabolic risk (680.0 μmol/L; 95 % CI, 510.2-849.8; P = 0.001) compared to healthy individuals (535.9 μmol/L; 95 % CI, 384.2-687.6). A significant positive association (coefficient, 15.4 [95 % CI, 0.255 to 30.5], P = 0.046) was observed between salivary NO(3)(-) and diastolic blood pressure (DBP). These findings suggest that the health status is positively associated with plasma NO(3)(-) and NO(2)(-) concentrations, but the circulatory levels of these anions are not associated with blood pressure. Only salivary NO(3)(-) showed a significant positive association with DBP.@article{bescos2025nitrate,
abstract = {In this study, we conducted a systematic review and meta-analysis to determine plasma and salivary nitrate (NO(3)(-)) and nitrite (NO(2)(-)) concentrations under resting and fasting conditions in different type of individuals and their association with blood pressure levels. A total of 77 studies, involving 1918 individuals aged 19-74 years (males = 906; females = 1012), which measured plasma and/or salivary NO(3)(-) and NO(2)(-) using the chemiluminescence technique, were included. Mean plasma NO(3)(-) and NO(2)(-) concentrations were 33.9 μmol/L and 158.3 nmol/L, respectively. Subgroup analyses revealed lower plasma NO(3)(-) and NO(2)(-) concentrations in individuals with cardiometabolic risk (NO(3)(-): 21.2 μmol/L; 95 % CI, 13.4-29.0; NO(2)(-): 122.8 nmol/L; 95 % CI, 75.3-138.9) compared to healthy (NO(3)(-): 33.9 μmol/L; 95 % CI, 29.9-37.9; NO(2)(-): 159.5 nmol/L; 95 % CI, 131.8-187.1; P < 0.01) and trained individuals (NO(3)(-): 43.0 μmol/L; 95 % CI, 13.2-72.9; NO(2)(-): 199.3 nmol/L; 95 % CI, 117.6-281; P < 0.01). Mean salivary NO(3)(-) and NO(2)(-) concentrations were 546.2 μmol/L and 197.8 μmol/L, respectively. Salivary NO(3)(-), but no NO(2)(-), concentrations were higher in individuals with cardiometabolic risk (680.0 μmol/L; 95 % CI, 510.2-849.8; P = 0.001) compared to healthy individuals (535.9 μmol/L; 95 % CI, 384.2-687.6). A significant positive association (coefficient, 15.4 [95 % CI, 0.255 to 30.5], P = 0.046) was observed between salivary NO(3)(-) and diastolic blood pressure (DBP). These findings suggest that the health status is positively associated with plasma NO(3)(-) and NO(2)(-) concentrations, but the circulatory levels of these anions are not associated with blood pressure. Only salivary NO(3)(-) showed a significant positive association with DBP.},
address = {United States},
author = {Bescos, Raul and Gallardo-Alfaro, Laura and Ashor, Ammar and Rizzolo-Brime, Lucia and Siervo, Mario and Casas-Agustench, Patricia},
journal = {Free radical biology & medicine},
keywords = {grapp-caib},
month = {jan},
pages = {70--83},
title = {Nitrate and nitrite bioavailability in plasma and saliva: Their association with blood pressure - A systematic review and meta-analysis},
volume = 226,
year = 2025
}%0 Journal Article
%1 bescos2025nitrate
%A Bescos, Raul
%A Gallardo-Alfaro, Laura
%A Ashor, Ammar
%A Rizzolo-Brime, Lucia
%A Siervo, Mario
%A Casas-Agustench, Patricia
%C United States
%D 2025
%J Free radical biology & medicine
%P 70--83
%R 10.1016/j.freeradbiomed.2024.11.010
%T Nitrate and nitrite bioavailability in plasma and saliva: Their association with blood pressure - A systematic review and meta-analysis
%U https://pubmed.ncbi.nlm.nih.gov/39522567
%V 226
%X In this study, we conducted a systematic review and meta-analysis to determine plasma and salivary nitrate (NO(3)(-)) and nitrite (NO(2)(-)) concentrations under resting and fasting conditions in different type of individuals and their association with blood pressure levels. A total of 77 studies, involving 1918 individuals aged 19-74 years (males = 906; females = 1012), which measured plasma and/or salivary NO(3)(-) and NO(2)(-) using the chemiluminescence technique, were included. Mean plasma NO(3)(-) and NO(2)(-) concentrations were 33.9 μmol/L and 158.3 nmol/L, respectively. Subgroup analyses revealed lower plasma NO(3)(-) and NO(2)(-) concentrations in individuals with cardiometabolic risk (NO(3)(-): 21.2 μmol/L; 95 % CI, 13.4-29.0; NO(2)(-): 122.8 nmol/L; 95 % CI, 75.3-138.9) compared to healthy (NO(3)(-): 33.9 μmol/L; 95 % CI, 29.9-37.9; NO(2)(-): 159.5 nmol/L; 95 % CI, 131.8-187.1; P < 0.01) and trained individuals (NO(3)(-): 43.0 μmol/L; 95 % CI, 13.2-72.9; NO(2)(-): 199.3 nmol/L; 95 % CI, 117.6-281; P < 0.01). Mean salivary NO(3)(-) and NO(2)(-) concentrations were 546.2 μmol/L and 197.8 μmol/L, respectively. Salivary NO(3)(-), but no NO(2)(-), concentrations were higher in individuals with cardiometabolic risk (680.0 μmol/L; 95 % CI, 510.2-849.8; P = 0.001) compared to healthy individuals (535.9 μmol/L; 95 % CI, 384.2-687.6). A significant positive association (coefficient, 15.4 [95 % CI, 0.255 to 30.5], P = 0.046) was observed between salivary NO(3)(-) and diastolic blood pressure (DBP). These findings suggest that the health status is positively associated with plasma NO(3)(-) and NO(2)(-) concentrations, but the circulatory levels of these anions are not associated with blood pressure. Only salivary NO(3)(-) showed a significant positive association with DBP.
AbstractURLBibTeXEndNoteDOIBibSonomy1.Marina Arroyo M, Ramírez Gallegos I, Paublini H, López-González Ángel A, Tárraga López PJ, Martorell Sánchez C, Sastre-Alzamora T, Ramírez-Manent JI. Usefulness of the Córdoba Equation for Estimating Body Fat When Determining the Level of Risk of Developing Diabetes Type 2 or Prediabetes. Medicina (Kaunas, Lithuania) [Internet]. Switzerland; 2025 Mar.;61(4):613-. https://pubmed.ncbi.nlm.nih.gov/40282904Background and Objectives: Type 2 diabetes (T2D) and prediabetes represent major global health concerns, with obesity being a key risk factor. However, recent evidence suggests that the adipose tissue composition and distribution play a more critical role in metabolic dysfunction than the total body weight or body mass index (BMI). This study evaluates the predictive capacity of the Córdoba Equation for Estimating Body Fat (ECORE-BF) for identifying individuals at high risk of developing T2D and prediabetes. Materials and Methods: A cross-sectional study was carried out involving 418,343 Spanish workers. Body fat percentage was estimated using the ECORE-BF equation, and diabetes risk was assessed using validated predictive models, including the Finnish Diabetes Risk Score (FINDRISC), QDiabetes score (QD-score), and others. The discriminatory power of ECORE-BF in predicting T2D and prediabetes was assessed using receiver operating characteristic (ROC) curve analysis. Results: ECORE-BF showed a strong correlation with high-risk classifications across all diabetes risk scales. The area under the ROC curve (AUC) exceeded 0.95 for both men and women, demonstrating high predictive accuracy. Conclusions: Adipose tissue distribution, particularly visceral adiposity, is a central factor in metabolic dysfunction. ECORE-BF provides a cost-effective alternative for large-scale T2D and prediabetes risk assessment. Future research should explore the impact of visceral adipose tissue reduction on diabetes prevention and the integration of estimation scales into clinical and public health strategies.@article{marinaarroyo2025usefulness,
abstract = {Background and Objectives: Type 2 diabetes (T2D) and prediabetes represent major global health concerns, with obesity being a key risk factor. However, recent evidence suggests that the adipose tissue composition and distribution play a more critical role in metabolic dysfunction than the total body weight or body mass index (BMI). This study evaluates the predictive capacity of the Córdoba Equation for Estimating Body Fat (ECORE-BF) for identifying individuals at high risk of developing T2D and prediabetes. Materials and Methods: A cross-sectional study was carried out involving 418,343 Spanish workers. Body fat percentage was estimated using the ECORE-BF equation, and diabetes risk was assessed using validated predictive models, including the Finnish Diabetes Risk Score (FINDRISC), QDiabetes score (QD-score), and others. The discriminatory power of ECORE-BF in predicting T2D and prediabetes was assessed using receiver operating characteristic (ROC) curve analysis. Results: ECORE-BF showed a strong correlation with high-risk classifications across all diabetes risk scales. The area under the ROC curve (AUC) exceeded 0.95 for both men and women, demonstrating high predictive accuracy. Conclusions: Adipose tissue distribution, particularly visceral adiposity, is a central factor in metabolic dysfunction. ECORE-BF provides a cost-effective alternative for large-scale T2D and prediabetes risk assessment. Future research should explore the impact of visceral adipose tissue reduction on diabetes prevention and the integration of estimation scales into clinical and public health strategies.},
address = {Switzerland},
author = {Marina Arroyo, Marta and Ramírez Gallegos, Ignacio and Paublini, Hernán and López-González, Ángel Arturo and Tárraga López, Pedro J and Martorell Sánchez, Cristina and Sastre-Alzamora, Tomás and Ramírez-Manent, José Ignacio},
journal = {Medicina (Kaunas, Lithuania)},
keywords = {grapp-caib},
month = {mar},
number = 4,
pages = {613--},
title = {Usefulness of the Córdoba Equation for Estimating Body Fat When Determining the Level of Risk of Developing Diabetes Type 2 or Prediabetes},
volume = 61,
year = 2025
}%0 Journal Article
%1 marinaarroyo2025usefulness
%A Marina Arroyo, Marta
%A Ramírez Gallegos, Ignacio
%A Paublini, Hernán
%A López-González, Ángel Arturo
%A Tárraga López, Pedro J
%A Martorell Sánchez, Cristina
%A Sastre-Alzamora, Tomás
%A Ramírez-Manent, José Ignacio
%C Switzerland
%D 2025
%J Medicina (Kaunas, Lithuania)
%N 4
%P 613--
%R 10.3390/medicina61040613
%T Usefulness of the Córdoba Equation for Estimating Body Fat When Determining the Level of Risk of Developing Diabetes Type 2 or Prediabetes
%U https://pubmed.ncbi.nlm.nih.gov/40282904
%V 61
%X Background and Objectives: Type 2 diabetes (T2D) and prediabetes represent major global health concerns, with obesity being a key risk factor. However, recent evidence suggests that the adipose tissue composition and distribution play a more critical role in metabolic dysfunction than the total body weight or body mass index (BMI). This study evaluates the predictive capacity of the Córdoba Equation for Estimating Body Fat (ECORE-BF) for identifying individuals at high risk of developing T2D and prediabetes. Materials and Methods: A cross-sectional study was carried out involving 418,343 Spanish workers. Body fat percentage was estimated using the ECORE-BF equation, and diabetes risk was assessed using validated predictive models, including the Finnish Diabetes Risk Score (FINDRISC), QDiabetes score (QD-score), and others. The discriminatory power of ECORE-BF in predicting T2D and prediabetes was assessed using receiver operating characteristic (ROC) curve analysis. Results: ECORE-BF showed a strong correlation with high-risk classifications across all diabetes risk scales. The area under the ROC curve (AUC) exceeded 0.95 for both men and women, demonstrating high predictive accuracy. Conclusions: Adipose tissue distribution, particularly visceral adiposity, is a central factor in metabolic dysfunction. ECORE-BF provides a cost-effective alternative for large-scale T2D and prediabetes risk assessment. Future research should explore the impact of visceral adipose tissue reduction on diabetes prevention and the integration of estimation scales into clinical and public health strategies.
AbstractURLBibTeXEndNoteDOIBibSonomy1.Obrador de Hevia J, López-González Ángel A, Ramírez-Manent JI, Paublini H, Tárraga López PJ, Martorell Sánchez C, Riutord-Sbert P. Association Between Alcohol Consumption, Other Healthy Habits and Sociodemographic Variables and the Values of Different Insulin Resistance Risk Scales in 139,634 Spanish Workers. Healthcare (Basel, Switzerland) [Internet]. Switzerland; 2025 Apr.;13(8):921-. https://pubmed.ncbi.nlm.nih.gov/40281870Background: Alcohol consumption is a major public health concern, influencing metabolic health and insulin resistance (IR). While moderate alcohol intake has been associated with potential metabolic benefits, excessive consumption is linked to IR and related disorders. This study examines the association between sociodemographic variables, health habits, and IR risk using validated metabolic indices. Methods: A dual-phase study was conducted, including a cross-sectional analysis of 139,634 Spanish workers and a retrospective longitudinal follow-up of 40,431 participants (2009-2019). Data on sociodemographic factors (age, sex and socioeconomic status) and health habits (smoking, alcohol consumption, diet and physical activity) were collected through standardized occupational health assessments. IR risk was assessed using the Triglyceride-Glucose Index (TyG), Metabolic Score for Insulin Resistance (METS-IR), and Single-Point Insulin Sensitivity Estimator (SPISE-IR). Binary logistic regression was used for statistical analysis. Results: Age, male sex, lower socioeconomic status, smoking, alcohol consumption, physical inactivity and low adherence to the Mediterranean diet were significantly associated with higher IR risk across all indices (p < 0.001). Alcohol consumption exhibited a dose-dependent relationship with IR, with excessive intake significantly increasing the risk of IR. Longitudinal data revealed a worsening IR profile over time, particularly among older, low-income and physically inactive individuals. Conclusions: Sociodemographic factors and lifestyle habits strongly influence IR. Preventive strategies focused on reducing alcohol consumption, smoking cessation and promoting physical activity and dietary improvements are essential to mitigate the risk of IR, especially in vulnerable populations. Further longitudinal studies are needed to establish causal relationships and refine intervention strategies.@article{obradordehevia2025association,
abstract = {Background: Alcohol consumption is a major public health concern, influencing metabolic health and insulin resistance (IR). While moderate alcohol intake has been associated with potential metabolic benefits, excessive consumption is linked to IR and related disorders. This study examines the association between sociodemographic variables, health habits, and IR risk using validated metabolic indices. Methods: A dual-phase study was conducted, including a cross-sectional analysis of 139,634 Spanish workers and a retrospective longitudinal follow-up of 40,431 participants (2009-2019). Data on sociodemographic factors (age, sex and socioeconomic status) and health habits (smoking, alcohol consumption, diet and physical activity) were collected through standardized occupational health assessments. IR risk was assessed using the Triglyceride-Glucose Index (TyG), Metabolic Score for Insulin Resistance (METS-IR), and Single-Point Insulin Sensitivity Estimator (SPISE-IR). Binary logistic regression was used for statistical analysis. Results: Age, male sex, lower socioeconomic status, smoking, alcohol consumption, physical inactivity and low adherence to the Mediterranean diet were significantly associated with higher IR risk across all indices (p < 0.001). Alcohol consumption exhibited a dose-dependent relationship with IR, with excessive intake significantly increasing the risk of IR. Longitudinal data revealed a worsening IR profile over time, particularly among older, low-income and physically inactive individuals. Conclusions: Sociodemographic factors and lifestyle habits strongly influence IR. Preventive strategies focused on reducing alcohol consumption, smoking cessation and promoting physical activity and dietary improvements are essential to mitigate the risk of IR, especially in vulnerable populations. Further longitudinal studies are needed to establish causal relationships and refine intervention strategies.},
address = {Switzerland},
author = {Obrador de Hevia, Joan and López-González, Ángel Arturo and Ramírez-Manent, José Ignacio and Paublini, Hernán and Tárraga López, Pedro Juan and Martorell Sánchez, Cristina and Riutord-Sbert, Pere},
journal = {Healthcare (Basel, Switzerland)},
keywords = {grapp-caib},
month = {apr},
number = 8,
pages = {921--},
title = {Association Between Alcohol Consumption, Other Healthy Habits and Sociodemographic Variables and the Values of Different Insulin Resistance Risk Scales in 139,634 Spanish Workers},
volume = 13,
year = 2025
}%0 Journal Article
%1 obradordehevia2025association
%A Obrador de Hevia, Joan
%A López-González, Ángel Arturo
%A Ramírez-Manent, José Ignacio
%A Paublini, Hernán
%A Tárraga López, Pedro Juan
%A Martorell Sánchez, Cristina
%A Riutord-Sbert, Pere
%C Switzerland
%D 2025
%J Healthcare (Basel, Switzerland)
%N 8
%P 921--
%R 10.3390/healthcare13080921
%T Association Between Alcohol Consumption, Other Healthy Habits and Sociodemographic Variables and the Values of Different Insulin Resistance Risk Scales in 139,634 Spanish Workers
%U https://pubmed.ncbi.nlm.nih.gov/40281870
%V 13
%X Background: Alcohol consumption is a major public health concern, influencing metabolic health and insulin resistance (IR). While moderate alcohol intake has been associated with potential metabolic benefits, excessive consumption is linked to IR and related disorders. This study examines the association between sociodemographic variables, health habits, and IR risk using validated metabolic indices. Methods: A dual-phase study was conducted, including a cross-sectional analysis of 139,634 Spanish workers and a retrospective longitudinal follow-up of 40,431 participants (2009-2019). Data on sociodemographic factors (age, sex and socioeconomic status) and health habits (smoking, alcohol consumption, diet and physical activity) were collected through standardized occupational health assessments. IR risk was assessed using the Triglyceride-Glucose Index (TyG), Metabolic Score for Insulin Resistance (METS-IR), and Single-Point Insulin Sensitivity Estimator (SPISE-IR). Binary logistic regression was used for statistical analysis. Results: Age, male sex, lower socioeconomic status, smoking, alcohol consumption, physical inactivity and low adherence to the Mediterranean diet were significantly associated with higher IR risk across all indices (p < 0.001). Alcohol consumption exhibited a dose-dependent relationship with IR, with excessive intake significantly increasing the risk of IR. Longitudinal data revealed a worsening IR profile over time, particularly among older, low-income and physically inactive individuals. Conclusions: Sociodemographic factors and lifestyle habits strongly influence IR. Preventive strategies focused on reducing alcohol consumption, smoking cessation and promoting physical activity and dietary improvements are essential to mitigate the risk of IR, especially in vulnerable populations. Further longitudinal studies are needed to establish causal relationships and refine intervention strategies.
